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Abstract 
Background 
Natural products could play an important role in the challenge to discover new anti-malarial 
drugs. In a previous study, Dicoma tomentosa (Asteraceae) was selected for its promising 
anti-plasmodial activity after a preliminary screening of several plants traditionally used in 
Burkina Faso to treat malaria. The aim of the present study was to further investigate the anti-
plasmodial properties of this plant and to isolate the active anti-plasmodial compounds. 
Methods 
Eight crude extracts obtained from D. tomentosa whole plant were tested in vitro against two 
Plasmodium falciparum strains (3D7 and W2) using the p-LDH assay (colorimetric method). 
The Peters’ four-days suppressive test model (Plasmodium berghei-infected mice) was used 
to evaluate the in vivo anti-plasmodial activity. An in vitro bioguided fractionation was 
undertaken on a dichloromethane extract, using preparative HPLC and TLC techniques. The 
identity of the pure compound was assessed using UV, MS and NMR spectroscopic analysis. 
In vitro cytotoxicity against WI38 human fibroblasts (WST-1 assay) and haemolytic activity 
were also evaluated for extracts and pure compounds in order to check selectivity. 
Results 
The best in vitro anti-plasmodial results were obtained with the dichloromethane, 
diethylether, ethylacetate and methanol extracts, which exhibited a high activity (IC50 ≤ 5 
μg/ml). Hot water and hydroethanolic extracts also showed a good activity (IC50 ≤ 15 μg/ml), 
which confirmed the traditional use and the promising anti-malarial potential of the plant. 
The activity was also confirmed in vivo for all tested extracts. However, most of the active 
extracts also exhibited cytotoxic activity, but no extract was found to display any haemolytic 
activity. The bioguided fractionation process allowed to isolate and identify a sesquiterpene 
lactone (urospermal A-15-O-acetate) as the major anti-plasmodial compound of the plant 
(IC50 < 1 μg/ml against both 3D7 and W2 strains). This was also found to be the main 
cytotoxic compound (SI =3.3). While this melampolide has already been described in the 
plant, this paper is the first report on the biological properties of this compound. 
Conclusions 
The present study highlighted the very promising anti-plasmodial activity of D. tomentosa 
and enabled to identify its main active compound, urospermal A-15-O-acetate. The high anti-
plasmodial activity of this compound merits further study about its anti-plasmodial 
mechanism of action. The active extracts of D. tomentosa, as well as urospermal A 15-O-
acetate, displayed only a moderate selectivity, and further studies are needed to assess the 
safety of the use of the plant by the local population. 
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Background 
Chemotherapeutic treatment of malaria has evolved in the last ten years due to the spread of 
multi-resistant Plasmodium falciparum strains. The World Health Organization (WHO) 
currently promotes artemisinin-based combination therapy (ACT) as the reference medicine 
for health care management of uncomplicated falciparum malaria in order to reduce the risk 
of resistance [1]. However, some signs of resistance to artemisinin have recently been 
detected in Asia [2-4], representing an enormous threat for the control of the disease. The 
discovery of new anti-malarial drugs is urgently needed and natural products could play an 
important role in this new challenge. 
The plant kingdom has been and remains a good source of pharmacologically active 
compounds and especially anti-plasmodial agents, as attested by quinine, isolated from 
Cinchona sp., and artemisinin extracted from Artemisia annua. Besides these well-known 
examples, various new anti-plasmodial natural compounds are frequently being discovered, 
as reviewed by several authors in recent years [5-9]. 
WHO estimates that up to 80 % of the world's population relies on traditional medicinal 
products for some aspects of primary health care [10,11]. Many people living in developing 
countries do not have access to modern therapeutics, such as ACT, to treat malaria because of 
financial, socio-economical, geographical and/or cultural reasons, and they use plants, often 
in combination, for the health care management of malaria. 
The search for new anti-malarial natural products, following an ethnopharmacological 
strategy (based on traditional knowledge of plants), has led to interesting results, as reviewed 
and commented on by Willcox et al. [12,13]. 
Moreover, there is now evidence that some whole plant extracts can be more active than 
single compounds, as a result of synergy and positive interactions between different 
constituents in the extracts, compared to a single product [14,15]. 
In this context, the pharmacological and phytochemical study of plants from traditional 
pharmacopoeias can be of interest, not only in discovering new anti-malarial “lead 
compounds”, but also in valorizing local vegetal species whose efficacy and safety has been 
demonstrated in laboratory and clinical investigations [16]. 
Better knowledge of plants from traditional pharmacopoeias and local valorization of 
traditional remedies in improved traditional medicine (ITM) could lead to effective, 
standardized, available and affordable therapeutics for the management of malaria by local 
populations, when modern drugs are unavailable [17]. 
Validated anti-malarial phytomedicines formulated from traditional medicines have been 
reported in recent years. Some are government approved in different countries, e g, Argemone 
mexicana in Mali, whose anti-malarial activity has been confirmed in clinical trials[18], and 
“Saye” in Burkina Faso, a combination of three plants, used for several years as a curative 
anti-malarial and recently studied for its benefits in the prophylaxis of malaria [19]. 
In a previous study dealing with the screening of several plants used in Burkina Faso in the 
traditional treatment of malaria, Dicoma tomentosa was selected for its promising anti-
plasmodial activity [20]. 
Dicoma tomentosa is a plant of the Asteraceae family growing in Asia and tropical Africa. It 
is an uncommon species, mainly found in the Sahelo-Sudanian area. Called “Gômtigdà” in 
the local language (Mooré), the decoction of the whole plant is traditionally used in Burkina 
Faso to treat malaria in adults and children, particularly malaria with spleen and liver 
“inflammation” [21]. The plant is also known for its benefits against cough and in postnatal 
care to “wash the belly”, but it is not recommended for pregnant women because it is known 
to cause abortion. 
The plant has been described as containing several sesquiterpene lactones [22-24], triterpenes 
and sterols [25,26] as well as flavonoids [27-30], but has never been studied for any 
biological or pharmacological properties. 
The aim of the present study was to further evaluate the anti-plasmodial potential of D. 
tomentosa using in vitro and in vivo models. In vitro cytotoxic and haemolytic properties 
were also studied in order to check the selectivity of the plant and thereby to appreciate its 
safety of use. 
Finally, a bioguided fractionation was undertaken to complete the study. This phytochemical 
analysis led to the isolation and identification of the major active compound. 
Methods 
Plant material 
Dicoma tomentosa whole plant (400 g) was collected in Poun, province of Sanguié, Burkina 
Faso in October 2008. The sample was authenticated by the Herbarium of the National 
Botanic Garden of Belgium, at Meise (Belgium). A voucher specimen was deposited in the 
same Herbarium under the number BR0000005088959. The plant material was washed and 
dried in a ventilated room (30 °C) and then ground to a powder. 
Preparation of crude extracts 
Eight crude extracts were prepared using eight different solvents: petroleum ether, hexane, 
dichloromethane, diethylether, ethylacetate, methanol, ethanol/water (50 %, v/v) and hot 
water. For each solvent, 5 g of dried plant powder were macerated with 50 ml of solvent, 
while being shaken for 30 minutes with a magnetic stirrer. This step was repeated twice. The 
preparations were filtered and evaporated under reduced pressure. 
For the aqueous crude extract, we prepared a decoction of 5 g dried plant powder in 150 ml 
distilled water for 90 min in order to approximate the traditional preparation method. The 
preparation was then filtered and freeze dried. 
In vitro anti-plasmodial assays 
Culture 
Continuous cultures of P. falciparum, chloroquine-sensitive (3D7) and chloroquine-resistant 
(W2) strains were maintained as described by Frédérich et al. [31]. Both strains were 
obtained from Prof Grellier (Museum National d’Histoire Naturelle, Paris, France). 
Assay 
The in vitro anti-plasmodial assay reproduces the erythrocytic development stage of the 
parasite and was performed as previously described [20]. Each of the eight crude extracts was 
first dissolved in DMSO (Sigma) at a concentration of 10 mg/ml (5 mg/ml for pure 
compound). Plasmodium falciparum culture was placed in contact with a set of eight two-
fold dilutions in the medium of each extract on two columns of a 96-well microplate for 48 h 
(final concentrations ranging from 0.8 (0.4) to 100 (50) μg/ml and final DMSO concentration 
≤1 %, each condition in duplicate). Parasite growth was estimated by colorimetric revelation 
and measurement of absorbance at 630 nm with a multiwell scanner (Stat Fax 2100, 
Awareness Technology Inc). The test is based on the evaluation of the plasmodial lactate 
dehydrogenase (pLDH) activity and was performed according to the method of Makler et al. 
[32] and as described previously by Kenmogne et al. [33]. Artemisinin (Sigma–Aldrich) and 
chloroquine (Sigma–Aldrich) were used as positive standards, and infected and uninfected 
erythrocytes were added as positive and negative controls, respectively. The inhibition of 
growth was calculated by comparison with the infected non-treated erythrocytes (=100 % 
growth). IC50 values, indicating the concentration of the drug needed to obtain 50 % 
inhibition of parasite growth, were calculated by linear regression from a set of eight 
concentrations tested for each extract/pure compound. Each sample was tested three times (3 
independent assays, n = 3) for each plasmodial strain. 
In line with WHO guidelines and basic criteria for antiparasitic drug discovery [34,35], 
activities of extracts were classified into four classes according to their IC50 values: high 
activity (IC50 ≤5 μg/ml); promising activity (5 μg/ml < IC50 ≤15 μg/ml); moderate activity (15 
μg/ml < IC50 ≤50 μg/ml); weak activity (IC50 >50 μg/ml). A pure compound is defined as 
highly active when its IC50 ≤1 μg/ml. 
In vitro cytotoxicity assays 
Culture 
WI-38 normal human fœtal lung fibroblasts were maintained in continuous culture in DMEM 
medium (Bio Whittaker) in a humid atmosphere at 37 °C and 5.5 % CO2. Each medium was 
supplemented with 10 % heat-inactivated fœtal bovine serum (Bio Whittaker), 1 % L-
glutamine (200 mM) (Bio Whittaker) and antibiotics: penicillin (100 UI/ml) – streptomycin 
(100 μg/ml) (Pen-strep®, Bio Whittaker). 
Assays 
Each of the eight crude extracts was first dissolved in DMSO (Sigma) to a concentration of 
10 mg/ml (5 mg/ml for pure compound). For the assays, 96-well tissue culture microplates 
(Micro Test-96®, Falcon, Becton-Dickinson) were seeded with 200 μl medium containing 
8,000 cells in suspension. 
After 24 h incubation, cells were treated with six dilutions at a final concentration of crude 
extracts in culture medium of 1, 5, 10, 25, 50 and 100 μg/ml (half concentration for pure 
compounds) and a final DMSO concentration ≤1 %. After 48 h incubation, cell viability was 
determined by adding WST-1 (Roche Biomolecular) tetrazolium salt as a cytotoxicity 
indicator and by reading absorbance at 450 nm with a scanning multiwell spectrophotometer 
(Stat Fax 2100, Awareness Technology Inc) after about a one-hour wait. Tetrazolium salts 
are cleaved to formazan dye by cellular enzymes. The absorbance directly correlates to the 
viable cell number. Each condition was reproduced in triplicate and each set of tests was 
performed twice. Camptothecin (Sigma-Aldrich) was used as a positive cytotoxic control. 
The inhibition of growth was calculated by comparison with the negative control (non-treated 
cells). IC50 values, indicating the concentration of the drug needed to obtain 50 % inhibition 
of cell growth, were calculated by linear regression from a set of six concentrations tested for 
each extract. 
Selectivity index (SI) 
The SI value allows the evaluation of the selective activity of the extracts/pure compound 
against the parasite compared to its toxicity for human cells. The SI value is calculated as the 
ratio between cytotoxic IC50 values and 3D7 or W2 parasitic IC50 values. 
In vitro haemolysis assays 
Haemolysis assays were conducted with the eight crude extracts and isolated pure compound, 
according to a previously described procedure [36]. Briefly, red blood cells suspensions (10 
% in PBS (v/v)) were incubated under agitation at room temperature for one hour with extract 
or pure compound solutions (final concentration = 100 μg/ml and DMSO <1 %). The 
mixtures were then centrifuged at room temperature for 5 min at 10,000 × g and the 
absorbance (OD) of the supernatants was measured at 550 nm with a microplate reader (Stat 
Fax 2100, Awareness Technology Inc). The crude extracts/pure compound were tested in 
triplicate at a final concentration of 100 μg/ml. Triton X-100 1 % (v/v) was used as a positive 
control (100 % red blood cell lysis) and PBS as a negative control (0 % red blood cell lysis). 
The red blood cell lysis percentage (H) was determined as follows: H = (OD550nm sample − 
OD550nm PBS)/(OD550nm Triton X-100 1 % − OD550nm PBS). The results were 
expressed as means ± SD with n = 3. 
In vivo anti-plasmodial assays 
The present study was approved by the Ethical Committee for the use of laboratory animals 
at the University of Liège (no. 721) and was designed according to the internationally 
recognized guidelines. Methanol, hydroethanolic and aqueous extracts of D. tomentosa were 
tested using a test protocol based on the four-day suppressive test of Peters [35]. Female 
Swiss mice (10 weeks of age, 25 ± 2 g), obtained from Charles River Laboratories (Brussels), 
were infected by the rodent parasite Plasmodium berghei NK173, following the protocol 
described in Frederich et al. [37]. Groups of five mice were formed randomly. The treatment 
doses (100 mg/kg ip or 300 mg/kg po, dissolved in 7 % Tween 80 and 3 % ethanol) were 
given intraperitoneally (methanol and hydroethanolic extracts) or orally (hydroethanolic and 
aqueous extracts), four hours after infection (day 0). The treatment was repeated once daily 
for the next three days (on days 1, 2 and 3 post-infection). On day 4 and day 7, thin blood 
smears were made from mouse-tail blood and were stained with Giemsa. Slides were 
inspected under the microscope and parasitaemia was determined by counting at least 500 
erythrocytes. Mice were controlled for their mortality for two weeks. Chloroquine 
diphosphate salt at 4 mg/kg (ip) was used as positive control and a methanol extract of the 
bark of Cinchona succirubra at 200 mg/kg (ip) was used as “positive plant extract control” 
due to the known presence of quinine in this Cinchona bark extract. This was used as a 
supplemental positive control to observe the profile of inhibition with a plant extract 
containing a known active ingredient. The vehicle solution (7 % Tween 80 and 3 % ethanol) 
was used as a negative control. 
Inhibition of Plasmodium growth (%) was calculated by comparison of the parasitaemia 
counted for the test group with the parasitaemia in the negative control group, at days 4 and 
7, respectively. Except for extracts tested by the oral route, which were tested once, the 
experiment was performed twice and the results represent means of inhibition of parasitaemia 
obtained for both experiments. 
Bioguided fractionation 
Extraction 
60 g of D. tomentosa whole plant powder were first percolated with 0.9 l of hexane followed 
by 1.8 l of dichloromethane to give 1.1 g of hexane extract (E1) and 1.9 g of dichloromethane 
extract (E2), respectively (yield E2 = 3.1 % (w/w)). 
TLC analysis 
Extracts and fractions were analysed by thin layer chromatography on Si60 silica gel plate 
(Merck) using dichloromethane-methanol (95:5) as the mobile phase. The plates were 
observed under UV light (254 and 366 nm) and then revealed by spraying of sulphuric 
vanillin reagent (2 % in ethanol (w/v)) and heating at 105 °C for 10 min. 
Preparative HPLC 
300 mg of the dichloromethane extract (E2) were dissolved in 11 ml of methanol–water 
(50:50). The solution was centrifuged, filtered (0.45 μ membrane) and injected into a 
reversed-phase preparative HPLC system using a Lichrospher RP-18 column (2.5x25 cm; 
12–15 μ, Merck packing system) as the stationary phase. The mobile phase consisted of 
methanol–water (50:50) in isocratic elution with a flow rate of 20 ml/min (Armen pump). 
Fractions of 10 ml were collected (Büchi fraction collector) and separation was monitored by 
TLC analysis. Fractions with the same TLC profiles were assembled to finally give 16 
fractions, designated F1 to F16. F16 (99.8 mg) was the insoluble part of the extract collected 
on the filter. F4 (10.2 mg) and F5 (67.3 mg) contained the main compound of the extract, as 
shown by TLC analysis. 
Preparative TLC 
10.2 mg of F4 were dissolved in 0.5 ml of dichloromethane and deposited on a preparative 
Si60 TLC plate (1.5 mm x 20 cm x 20 cm). Elution was performed with dichloromethane-
methanol (95:5) as the mobile phase. The band corresponding to the pure compound 1 was 
scratched off and extracted with a mixture of dichloromethane and methanol (50:50) using a 
G4 filter. The filtrate was evaporated under reduced pressure to give 8.0 mg of the pure 
compound 1 = urospermal-15-O-acetate. The same procedure was applied to 9.7 mg of F5 to 
give 7.8 mg of 1. 
Spectroscopic analysis 
The structure of compound 1 was elucidated using various spectroscopic techniques. NMR 
spectra (
1 H, 13C, COSY, HMBC, HSQC) were recorded in CDCl3 with a Bruker Avance 500 
MHz spectrometer equipped with a cryoprobe and using TMS as the internal reference. Mass 
spectrometry (MS) was carried out using a micromass ESI-Q-TOF II instrument (Waters) 
using ESI-ionization in positive mode. The UV spectrum was obtained with a methanol 
solution using a Kontron Uvikon Spectrophotometer. The identity of the purified compound 
1 was assessed by comparison of its NMR and MS data with data from the literature [22] 
(Additional file 1). 
Biological assays 
The fractions as well as E1 and E2 and 1 were tested against the 3D7 P. falciparum strain 
according to the protocol described above. The cytotoxic and haemolytic properties of 1 were 
also evaluated, as well as its anti-plasmodial activity against the W2 chloroquino-resistant 
strain. We used the same method as described for the crude extracts. 
Results and discussion 
In vitro and in vivo anti-plasmodial activity of crude extracts 
All eight tested extracts were found to be active against both chloroquine-sensitive 3D7 and -
resistant W2 strains of P. falciparum (IC50 < 50 μg/ml). IC50 values obtained with crude 
extracts are detailed in Table 1, as well as extraction yields from plants (w/w). 
Dichloromethane, diethylether, ethylacetate, and methanol extracts were found to be highly 
active with IC50 ≤ 5 μg/ml, while hydroethanolic and hot water extracts displayed a promising 
activity (IC50 ≤ 15 μg/ml). Petroleum ether and hexane extracts showed a lower level of 
activity. 
Table 1 In vitro anti-plasmodial, cytotoxic and haemolytic activity of crude extracts and pure compound (1) obtained from Dicoma 
tomentosa (n = 3) 
Pure compound Yield (in the 
plant) 
IC50 3D7 μg/ml 
(μM) 
IC50 W2 μg/ml 
(μM) 








Compound 1 = urospermal-15-O-acetate 
(MM = 320.34) 
0.64 % 0.92 ± 0.05  
(= 2.87 ± 0.16) 
0.77 ± 0.25  
(= 2.41 ± 0.78) 
3.03 ± 0.18  
( = 9.47 ± 0.56) 
3.3 3.9 < 1 % 








Petroleum ether 1.8 % 23.2 ± 3.1 21.2 ± 2.2 22.0 ± 0.6 0.9 1.0 < 1 % 
Hexane 1.7 % 18.7 ± 2.9 17.7 ± 1.2 32.9 ± 4.0 1.8 1.9 < 1 % 
Dichloromethane 5.4 % 3.4 ± 1.2 1.9 ± 0.2 11.5 ± 0.4 3.3 6.1 < 1 % 
Diethylether 3.4 % 3.9 ± 0.6 4.8 ± 0.7 6.5 ± 1.4 1.6 1.3 < 1 % 
Ethylacetate 4.1 % 4.4 ± 1.1 4.6 ± 0.3 5.9 ± 0.6 1.3 1.3 < 1 % 
Methanol 11.1 % 5.8 ± 2.0 3.0 ± 0.5 19.9 ± 5.4 3.5 6.7 < 1 % 
Ethanol 50 % (v/v) 16.2 % 12.9 ± 3.0 9.7 ± 1.1 28.4 ± 2.9 2.2 2.9 < 1 % 
Hot water 20.3 % 12.8 ± 2.4 6.7 ± 1.0 47.2 ± 2.9 3.7 7.0 < 1 % 
SI = selectivity index = IC50(WI38)/IC50(3D7 or W2, respectively) 
Standard drugs: artemisinin (3D7): IC50 = 0.0067 ± 0.0018 μg/ml; artemisinin (W2): IC50 = 0.0034 ± 0.0009 μg/ml; chloroquine (3D7): IC50 = 
0.016 ± 0.004 μg/ml; chloroquine (W2): IC50 = 0.35 ± 0.08 μg/ml; camptothecin (WI-38): IC50 = 0.029 ± 0.011 μg/ml 
The levels of activity observed with the dichloromethane, methanol and hot water extracts 
were about twice as high as the anti-plasmodial IC50 values obtained for the same extracts in 
the previous study. That previous study was conducted with a batch of D. tomentosa also 
collected in Burkina Faso, at the same time of year but in 2007 and in a different area (and 
with samples from stock maintained in less adequate storage conditions) [20]. The anti-
plasmodial activity obtained with this new batch was found to be in the same range as can be 
observed with Artemisia annua extracts [38]. The anti-plasmodial activity of the hot water 
extract supports the traditional use of this plant to treat malaria and is an interesting result 
when considering further prospects for its local valorization. 
In vivo experiments with methanol, hydroethanolic and aqueous extracts of D. tomentosa 
whole plant confirmed the anti-plasmodial activity of this Asteraceae. Both treatments given 
intraperitoneally (methanol and hydroethanolic extracts, 100 mg/kg) displayed an inhibition 
of parasitaemia in the range of 40-60 % at days 4 and 7. Unfortunately, both extracts were 
found to be toxic when the dose was increased to 200 mg/kg/day, i.p. (all the mice died 
before day 4). Both treatments given by oral route (hydroethanolic and hot water extracts, 
300 mg/kg) showed a much lower activity at day 4, but at day 7 the inhibition of Plasmodium 
growth was in the same range as for the extracts given intraperitoneally. Detailed results are 
presented in Figure 1. 
Figure 1 In vivo anti-plasmodial activity is expressed by the inhibition of the growth of 
Plasmodium berghei in infected mice treated with Dicoma tomentosa extracts compared 
to a non-treated negative control group of mice (growth = 100 %). Standard drug = 
chloroquine (4 mg/kg, ip) and Cinchona succirubra stem bark methanol extract (200 mg/kg, 
ip) MeOH = methanol; EtOH50% = Ethanol/Water 50 % (v/v); H20 = Hot water 
The inhibition of parasitaemia was thus maintained (for ip-tested extracts and Cinchona 
control extract) or improved (for po-tested extracts) between days 4 and 7, in contrast with 
chloroquine, for which the activity was high at day 4 but clearly decreased at day 7. The 
prolonged activity obtained with the plant extracts against the parasite indicates either a long 
half-life of the active compounds in the extract, or the implication of metabolization in the 
activity with production of active metabolites. That (as well as the gastrointestinal resorption 
process) could explain the delayed effect observed with oral treatments. 
Cytotoxic and haemolytic activity of crude extracts 
Additional in vitro studies concerning the haemolytic potential and the cytotoxic activity on 
normal human fibroblasts were also carried out in order to check the anti-plasmodial 
selectivity of D. tomentosa. Results are detailed in Table 1. 
No extract was found to exhibit significant red blood cells lysis activity with a percentage of 
haemolysis <1 % for all tested extracts (conc = 100 μg/ml). This indicates that anti-
plasmodial activity is not correlated with haemolysis of red blood cells but with a real action 
against the parasite. 
However, all eight extracts were found to be quite cytotoxic on WI38 cells (IC50 values from 
5.9 to 47.2 μg/ml) and showed a low to moderate selectivity (SI from 0.9 to 7.0, depending 
on the extract and the plasmodial strain). 
Bioguided fractionation: isolation and identification of the major active 
compound 
A bioguided fractionation was carried out in order to identify the compound(s) responsible 
for the anti-plasmodial activity. 
Preliminary TLC analysis of the CH2Cl2 crude extract revealed the presence of some major 
terpenic compounds in the plant, especially one grey spot (Rf ~0.65), using the sulphuric 
vanillin reagent. The intensity of this grey spot, named “compound 1”, seemed to be 
correlated with the in vitro anti-plasmodial activity of the different tested extracts. 
For the bioguided fractionation and depending on the results obtained with the eight crude 
extracts, powdered plant was first extracted by hexane (E1), followed by dichloromethane 
(E2 = “defatted extract” – yield =3.1 %). 
The activity of the extracts and fractions was evaluated against P. falciparum 3D7 strain. IC50 
values of E1 and E2 were 36.9 and 2.0 μg/ml, respectively. E2 containing compound 1 as the 
major compound was found to be even more active than the crude dichloromethane extract, 
while E1, found to contain the other major terpenes in TLC analysis, was much less active. 
E2 was submitted to preparative reversed-phase HPLC to give 16 fractions (F1-F16) 
(Additional file 2). 
All tested fractions obtained from E2 were found to possess high or promising anti-
plasmodial activity, with IC50 values ranging from 0.95 μg/ml (F4 and F5) to 6.9 μg/ml (F16). 
The significant activity detected in several fractions with different TLC profiles means that 
several compounds can be said to contribute to the overall in vitro anti-plasmodial properties 
of D. tomentosa dichloromethane extract. However, major compound 1 - the grey spot - was 
the main constituent of the two most active fractions F4 and F5 (respectively 10.2 mg and 
67.3 mg = 25.84 % E2 (w/w)) and this compound could therefore be considered as the major 
active compound in the plant. 
Compound 1, a terpene, was finally isolated as a pure compound after an additional 
preparative TLC step on F4 and F5 and was submitted to UV, MS/MS and NMR analysis. 
Compound 1 was identified as urospermal A-15-O-acetate, a melampolide-type 
sesquiterpene lactone (Figure 2). Its identity was confirmed by comparison of its spectral 
profile with spectral data available for known compounds in D. tomentosa [22]. 
Melampolides are 10-membered ring sesquiterpene lactones. They can be considered a 
subgroup of germacranolides but with a 1,10 cis-double bond configuration. 
Figure 2 urospermal A-15-O-acetate (MM = 320.34) 
Yield of urospermal A-15-O-acetate was estimated to 20.7 % (w/w) of the dichloromethane 
extract (E2), corresponding to 0.64 % (w/w) of the dried plant. 
Anti-plasmodial, cytotoxic and haemolytic properties of urospermal A-15-O-
acetate 
Purified compound 1 was also tested for its anti-plasmodial, cytotoxic and haemolytic 
properties. Results are presented in Table 1. Urospermal A-15-O-acetate was found to display 
a very strong anti-plasmodial activity with IC50 <1 μg/ml against both chloroquine-sensitive 
and -resistant P. falciparum strains. The contribution of this active compound to the activity 
of the dichloromethane extract (E2) can be estimated to 62.1 %, according to the method 
described by Deharo and Ginsburg [15]. This confirmed that urospermal A-15-O-acetate 
could be considered as the main active compound of the plant. It is likely that other minor 
closely related sesquiterpene lactones – such as the other germacranolides and melampolides 
already described in the plant [22,23] – also displayed additive/synergistic anti-plasmodial 
activity, as attested by the significant activity detected in almost all the fractions. Products 
from other phytochemical classes, such as flavonoids (already described in the plant [27-30]) 
could also play some role in the overall anti-plasmodial effect by several mechanisms, as 
widely described for A. annua [38,39]. 
No significant haemolytic activity was detected for 1. However, this sesquiterpene lactone 
appeared to be cytotoxic with IC50 = 3.0 μg/ml on WI38 human fibroblasts. The selectivity 
index (SI = 3.3) was the same as those obtained with the CH2Cl2 extract, which suggests that 
this major anti-plasmodial compound is the main cytotoxic product in the plant. 
Urospermal A-15-O-acetate has already been described as a major compound of D. 
tomentosa by Bolhmann et al. [22] for a batch collected in South Africa. The present study is, 
however, the first report of the compound’s anti-plasmodial and cytotoxic properties. 
Moreover, this compound has never been described in any other plant. 
Recently, another plant from the same genus, Dicoma anomala ssp gerrardii was described 
for its anti-plasmodial activity [40]. The main active compound in that plant was also a 
sesquiterpene lactone but of the eudesmanolide-type and represented 0.0013 % (w:w) of the 
dried plant powder. Cytotoxic activity was also detected for this compound in that study. 
Many sesquiterpene lactones isolated from Asteraceae have already been described as anti-
plasmodial and cytotoxic in the literature, such as (pseudo)guaianolides, eudesmanolides and 
also germacranolides/melampolides (e g, tagitinin C from Tithonia diversifolia [41] and 
recently acanthospermolide derivatives from Acanthospermum hispidum [42]). Structure–
activity relationship studies have shown that the α-methylene-γ-lactone moeity (or more 
widely, at least one potentially reactive α,β-unsaturated bond) is the main element needed for 
anti-plasmodial or cytotoxic activity of such compounds, and that antiprotozoal activity is 
significantly correlated with cytotoxicity [43,44]. The low selectivity of such compounds can 
be explained by the chemical reactivity of the α,β-unsaturated bond, especially towards free 
thiol groups (e g, cysteine residues in enzymes and transcription factors). 
Conclusions 
Dicoma tomentosa showed promising anti-plasmodial properties through in vitro and in vivo 
tests performed in the present study, and this supports the traditional use of this plant. 
However, the plant’s lack of selectivity would urge caution in its consumption by the local 
population. Further studies (e g, regarding genotoxicity, acute/chronic toxicity) are needed to 
assess the safe use of the plant. 
We found that the main active compound of the plant, urospermal A-15-O-acetate, showed a 
promising anti-plasmodial activity with a low but real selectivity. Its mechanism of action is 
currently under study. A pharmacomodulation process may need to be undertaken in order to 
decrease the compound’s toxicity while maintaining (or improving) its activity. On the other 
hand, its cytotoxic activity could also be investigated in the field of cancerology. 
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